Genvoya, Stribild, Tybost (elvitegravir/cobicistat) - Important Safety Information from Gilead Sciences Ltd as approved by HPRA

Notice type: 3rd Party Publications

Date: 28/03/2019


Problem Or Issue:
Important Safety Information communication from Gilead Sciences Ltd on increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy

Important Safety Information - Genvoya Stribild Tybost (elvitegravir cobicistat)

« Back